bioAffinity Technologies, Inc.
BIAF
$10.50
$1.5717.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -23.18% | -35.75% | -34.18% | -27.66% | 4.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.18% | -35.75% | -34.18% | -27.66% | 4.99% |
| Cost of Revenue | -28.37% | -34.45% | -29.36% | -19.67% | 14.11% |
| Gross Profit | -10.98% | -38.23% | -42.72% | -42.47% | -11.60% |
| SG&A Expenses | 14.02% | 4.83% | -0.30% | 6.06% | 11.86% |
| Depreciation & Amortization | -27.85% | -23.88% | -16.63% | -10.99% | 12.94% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.03% | -6.63% | -8.63% | -3.15% | 11.00% |
| Operating Income | -23.04% | -20.00% | -18.08% | -24.35% | -16.07% |
| Income Before Tax | -30.31% | -62.98% | -64.66% | -74.31% | -33.55% |
| Income Tax Expenses | -84.12% | 111.98% | 276.92% | 192.14% | 194.16% |
| Earnings from Continuing Operations | -29.91% | -63.07% | -64.94% | -74.51% | -33.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.91% | -63.07% | -64.94% | -74.51% | -33.80% |
| EBIT | -23.04% | -20.00% | -18.08% | -24.35% | -16.07% |
| EBITDA | -26.11% | -2.14% | 16.66% | 14.23% | 20.22% |
| EPS Basic | 66.94% | 46.93% | 31.02% | 13.49% | 22.87% |
| Normalized Basic EPS | 66.86% | 47.03% | 31.17% | 13.58% | 22.97% |
| EPS Diluted | 66.94% | 46.93% | 31.02% | 13.49% | 22.87% |
| Normalized Diluted EPS | 66.86% | 47.03% | 31.17% | 13.58% | 22.97% |
| Average Basic Shares Outstanding | 578.58% | 492.71% | 325.62% | 102.62% | 71.71% |
| Average Diluted Shares Outstanding | 578.58% | 492.71% | 325.62% | 102.62% | 71.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |